Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis

Median Overall Survival Nearly Double than Expected with Standard of Care Alone June 1, 2014 Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus’ Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. In this Phase …

Stemline Therapeutics Announces FDA Acceptance of Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors

April 8, 2014 Stemline Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for SL-701, which enables the company to advance SL-701 into a Phase 2 trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides engineered …